Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $35.50.
A number of research analysts have commented on the company. BTIG Research upped their price objective on Cullinan Therapeutics from $40.00 to $41.00 and gave the company a "buy" rating in a report on Wednesday, October 28th. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. Wall Street Zen cut shares of Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Friday, October 2nd. Finally, Wedbush upped their price target on shares of Cullinan Therapeutics from $42.00 to $44.00 and gave the company an "outperform" rating in a research note on Wednesday, November 11th.
Check Out Our Latest Stock Analysis on Cullinan Therapeutics
Insiders Place Their Bets
In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 4,000 shares of the business's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $12.36, for a total value of $49,440.00. Following the completion of the sale, the insider owned 158,649 shares of the company's stock, valued at $1,960,901.64. The trade was a 2.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.60% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in CGEM. Integrated Wealth Concepts LLC bought a new position in shares of Cullinan Therapeutics in the second quarter worth $25,000. GAMMA Investing LLC raised its stake in Cullinan Therapeutics by 38.3% in the third quarter. GAMMA Investing LLC now owns 2,666 shares of the company's stock valued at $41,000 after purchasing an additional 738 shares in the last quarter. Allworth Financial LP acquired a new position in Cullinan Therapeutics in the second quarter valued at about $53,000. Quantbot Technologies LP acquired a new position in Cullinan Therapeutics in the second quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Cullinan Therapeutics during the 3rd quarter worth approximately $50,000. 86.31% of the stock is owned by institutional investors.
Cullinan Therapeutics Stock Performance
Shares of CGEM opened at $8.89 on Friday. Cullinan Therapeutics has a 52 week low of $8.47 and a 52 week high of $23.19. The firm has a market cap of $576.88 million, a P/E ratio of -2.89 and a beta of -0.03. The firm's 50-day simple moving average is $14.65 and its 200 day simple moving average is $15.72.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.10. As a group, equities analysts forecast that Cullinan Therapeutics will post -3.09 earnings per share for the current year.
About Cullinan Therapeutics
(
Get Free Report)
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.